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Background. Descriptions of the pharmacokinetics and metabolism of morphine and its
metabolites in young children are scant. Previous studies have not differentiated the effects of
size from those related to age during infancy.
Methods. Postoperative children 0±3 yr old were given an intravenous loading dose of
morphine hydrochloride (100 mg kg±1 in 2 min) followed by either an intravenous mor-
phine infusion of 10 mg h±1 kg±1 (n=92) or 3-hourly intravenous morphine boluses of
30 mg kg±1 (n=92). Additional morphine (5 mg kg±1) every 10 min was given if the visual
analogue (VAS, 0±10) pain score was >4. Arterial blood (1.4 ml) was sampled within 5
min of the loading dose and at 6, 12 and 24 h for morphine, morphine-3-glucuronide
(M3G) and morphine-6-glucuronide (M6G). The disposition of morphine and formation
clearances of morphine base to its glucuronide metabolites and their elimination clear-
ances were estimated using non-linear mixed effects models.
Results. The analysis used 1856 concentration observations from 184 subjects.
Population parameter estimates and their variability (%) for a one-compartment, ®rst-
order elimination model were as follows: volume of distribution 136 (59.3) litres, forma-
tion clearance to M3G 64.3 (58.8) litres h±1, formation clearance to M6G 3.63 (82.2)
litres h±1, morphine clearance by other routes 3.12 litres h±1 per 70 kg, elimination
clearance of M3G 17.4 (43.0) litres h±1, elimination clearance of M6G 5.8 (73.8) litres
h±1. All parameters are standardized to a 70 kg person using allometric 3/4 power
models and re¯ect fully mature adult values. The volume of distribution increased expo-
nentially with a maturation half-life of 26 days from 83 litres per 70 kg at birth; forma-
tion clearance to M3G and M6G increased with a maturation half-life of 88.3 days from
10.8 and 0.61 litres h±1 per 70 kg respectively at birth. Metabolite formation decreased
with increased serum bilirubin concentration. Metabolite clearance increased with age
(maturation half-life 129 days), and appeared to be similar to that described for glomer-
ular ®ltration rate maturation in infants.
Conclusion. M3G is the predominant metabolite of morphine in young children and total
body morphine clearance is 80% that of adult values by 6 months. A mean steady-state serum
concentration of 10 ng ml±1 can be achieved in children after non-cardiac surgery in an
intensive care unit with a morphine hydrochloride infusion of 5 mg h±1 kg±1 at birth (term
neonates), 8.5 mg h±1 kg±1 at 1 month, 13.5 mg h±1 kg±1 at 3 months and 18 mg h±1 kg±1 at
1 year and 16 mg h±1 kg±1 for 1- to 3-yr-old children.
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Morphine is largely metabolized by uridine 5¢-diphosphate
glucuronosyltransferase UGT2B7 to morphine-3-glucuro-
nide (M3G) and morphine-6-glucuronide (M6G).1 In vitro
studies using liver microsomes from fetuses aged 15±27
weeks indicated that morphine glucuronidation was
approximately 10±20% of that seen with adult
microsomes.2 3 Morphine glucuronidation has been dem-
onstrated in premature infants as young as 24 weeks.
Morphine clearance is reported as 23.6 (SD 8.5) ml min±1 kg±1
in infants and children greater than 11 days old.4 Lynn and
colleagues5 report clearances greater on a per kg basis than
those of adults at 3 months of age. In a systematic review of
morphine metabolism, it was concluded that children older
than 1 month metabolize morphine like adults.6 The use of
the per kilogram size model (ml min±1 kg±1) has confused
interpretation of morphine developmental pharmacoki-
netics; underestimation occurs as size decreases.7
Anderson and colleagues8 revised published clearance
estimates from different age groups using a 3
4
power
allometric size model to demonstrate that adult values for
clearance are reached at about 6 months.
We had the opportunity to examine morphine and
metabolite serum concentrations in children 0±3 yr old
given either intermittent boluses or morphine infusion.9 10
These data have previously been analysed using multiple
regression to investigate the effect of clinical variables, such
as gestational age, sex, weight, the therapeutic regimens
used and mechanical ventilation, on morphine requirements
and plasma concentrations.10 That analysis revealed that age
was the most important factor affecting morphine require-
ments and plasma morphine concentrations. Signi®cantly
fewer neonates required additional morphine doses com-
pared with all other age groups and neonates had signi®-
cantly higher plasma concentrations of morphine.10
This study analysis further investigated and quanti®ed the
effect of age using a population-based approach that
included size as the primary covariate in an effort to
disentangle age-related factors from size-related factors.
Age-related morphine metabolite pharmacokinetics in chil-
dren have not been quanti®ed previously.
Methods
The study was approved by the hospital medical ethics
committee and written consent obtained from parents. The
methods have been described in an earlier publication.10
Children aged 0±3 yr, admitted to the paediatric surgical
intensive care unit after non-cardiac thoracic and abdominal
surgery, were considered for enrolment. Patients were
excluded if they had received morphine within 6 h before
surgery, or if they suffered from hepatic, renal or neuro-
logical disorders. Fentanyl, rather than morphine, was used
in incremental doses intraoperatively: 5 mg kg±1 was given
before orotracheal intubation, 5 mg kg±1 before surgical
incision and additional doses of 2 mg kg±1 when HR and/or
MAP were 15% above baseline values. The median amount
of fentanyl used during surgery was 5.3 (25th±75th centile,
3.8±6.9) mg kg±1. Patients were randomly assigned to
receive either intravenous morphine hydrochloride infusion
or intermittent morphine hydrochloride boluses. The
pharmacists randomized and prepared all study drugs.
Clinical staff were blinded to the study group allocation.
At the end of surgery, mechanical ventilation was
continued in patients who required ventilator assistance
after surgery. Directly after surgery, all patients were given
an intravenous loading dose of morphine hydrochloride
(100 mg kg±1 over 2 min), followed by either an infusion of
10 mg h±1 kg±1 combined with 3-hourly intravenous placebo
(saline) boluses over 2 min or a continuous placebo infusion
(saline) combined with 3-hourly intravenous morphine
hydrochloride boluses of 30 mg kg±1. Additional morphine
(5 mg kg±1 every 10 min) was given if the visual analogue
scale (VAS, 0±10) pain scores were >4. No other analgesic
or sedative drugs were used.
Arterial blood samples (1.4 ml) were taken after induc-
tion of anaesthesia (baseline), at the end of surgery, and 6,
12 and 24 h after surgery to determine serum concentrations
of morphine, M3G and M6G.
Pain was assessed 3-hourly by nurses trained in the use of
the behavioural part of the COMFORT score11 and VAS (0±
10). The VAS score was measured after the 2 min of
observation needed for the COMFORT score.11±14 Nursing
interventions included pain assessment, blood sampling and
administration of intermittent bolus (placebo or morphine)
medication.
Morphine and metabolite assay
Serum aliquots (0.6 ml) were extracted with the Baker-10
extraction system (Baker Chemicals, Deventer, The
Netherlands) ®tted with 1-ml disposable cyclohexyl cart-
ridges (C6H6, Baker, catalogue no. 7212-01). The extrac-
tion column was conditioned with two column volumes of
methanol, two column volumes of water and 1 ml of 500
mM diammonium sulphate (pH=9.3). The serum (0.6 ml)
was diluted with 0.6 ml 500 mM diammonium sulphate
(pH=9.3) and washed with 2 ml of 50 mM diammonium
sulphate (pH=9.3) after which it was allowed to dry for 15 s.
The elution was carried out with 0.5 ml 0.01 M KH2PO4
buffer, pH=2.1, containing 11% acetonitrile. From this
eluate, 50 ml was injected on the analytical column. The
HPLC system comprised a Spectro¯ow 400 solvent delivery
system (Kratos, Rotterdam, The Netherlands) equipped with
a degasser (Separations, HI-Ambacht, The Netherlands), a
Marathon auto sampler (Separations), a Spectro¯ow 773
UV detector at l=210 nm (Separations), in sequence with an
electrochemical detector (Interscience, Breda, The
Netherlands) equipped with an analytical cell (Model
5010). All compounds leave the UV detector chemically
intact, and so the electrochemically active components can
be oxidized in the electrochemical cell. This type of
electrochemical cell contains two separate analytical cells,
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which makes it possible to create a small window of applied
potential. The detector 2 potential was set at 0.4 V, while the
detector 1 potential was 0.3 V. This minimizes interfering
peaks because only compounds with an oxidation potential
from 0.3 to 0.4 V are recorded. Chromatographic separ-
ations were achieved using a Cp-Sper C8 column (25034.6
mm) (Chrompack, Bergen op Zoom, The Netherlands). The
mobile phase was a 0.01 M KH2PO4 buffer, pH=2.1,
containing 11% acetonitrile and heptane sulphonic acid 0.4
g litre±1.
In serum, all calibration graphs (containing six data
points) were linear: for M3G the concentrations ranged from
25 to 580 ng ml±1 (r=0.9992); for M6G from 5 to 100 ng
ml±1 (r=0.9982) and for morphine, from 5 to 90 ng ml±1
(r=0.9963). On average, the quantitation limit was 5 ng ml±1
for morphine and M6G and 25 ng ml±1 for M3G. However,
in individual samples the quality of the chromatogram was
inspected and allowed for a lower threshold when peaks
were clearly separated from baseline. In this concentration
range, the intra-day precision was less than 10% for all
compounds and the bias was about 5%.15 16 Standardized
automated laboratory analysers measured serum concentra-
tions of bilirubin and creatinine.
Morphine hydrochloride dose and M3G and M6G
concentrations were converted to anhydrous morphine
base equivalents using a molecular weight of 285 for
morphine, 322 for morphine hydrochloride and 461 for the
two glucuronide metabolites.
Modelling
Population parameter estimates were obtained using a non-
linear mixed effects model. This model accounts for random
between-subject parameter variability and residual variabil-
ity (random effects) as well as between-subject parameter
differences predicted by covariates (®xed effects). The
population parameter variability in model parameters was
modelled by an exponential variance model. The covariance
between clearance, distribution volume and absorption half-
life was incorporated into the model. A proportional term
characterized the residual unknown variability for mor-
phine. An additive and a proportional term characterized the
residual unknown variability for M3G and M6G concen-
trations. The population mean parameters, between-subject
variance and residual variances were estimated using
NONMEM version V release 1.1.17 Estimation used the
®rst-order conditional estimate method with the interaction
option and ADVAN 6 with Tol=5. The convergence
criterion was 3 signi®cant digits. A Compaq Digital
Fortran Version 6.6A compiler with Intel Celeron 333
MHz CPU (Intel, Santa Clara, CA, USA) under Microsoft
Windows XP (Microsoft, Seattle, WA, USA) was used to
compile NONMEM.
Differential equations were used to describe the pharma-
cokinetics of morphine and its metabolites.
CLT=CL2M3G+CL2M6G+CLEX
dCS/dt=(RATEIN±CS3CLT)/V
dM3G/dt=(CL2M3G3CS±CLM3G3CM3G)/V3M
dM6G/dt=(CL2M6G3CS±CLM6G3CM6G)/V6M
The model is shown in Figure 1. CLT is total morphine
clearance, V is the volume of distribution for morphine, CS
is morphine serum concentration, CL2M3G is formation
clearance to M3G, CM3G is the serum M3G concentration,
CL2M6G is formation clearance to M6G, CM6G is the
serum M6G concentration, CLM3G is the elimination
clearance of M3G, CLM6G is the elimination clearance of
M6G, VM is the volume of distribution of glucuronide
metabolites, CLEX is morphine clearance by other routes,
and RATEIN is the morphine infusion rate.
The metabolite volumes of distribution (V3M, V6M)
cannot be identi®ed with the present study design and were
®xed at 23 and 30 litres per 70 kg, based on previous studies
in adults.18 19
The parameter values were standardized for a body
weight of 70 kg using an allometric model:7 20
Pi=Pstd3(Wi/Wstd)
PWR
where Pi is the parameter in the ith individual, Wi is the
weight in the ith individual and Pstd is the parameter in an
individual with a weight (Wstd) of 70 kg. The PWR exponent
was 0.75 for clearance and 1 for distribution volumes.20±23
Exponential functions were applied to describe age-
related developmental changes in the formation of metabo-
lites (CL2M3G, CL2M6G), clearance of metabolites
(CLM3G, CLM6G) and morphine volume of distribution
(Table 3B):
Fig 1 Pharmacokinetic model. V is the volume of distribution for
morphine, CS is morphine serum concentration, CL2M3G is the
formation clearance to M3G, CM3G is the serum M3G concentration,
CL2M6G is the formation clearance to M6G, CM6G is the serum M6G
concentration, CLM3G is the elimination clearance of M3G, CLM6G is
the elimination clearance of M6G, VM is the volume of distribution of
glucuronide metabolites, CLEX is unaccounted clearance, and Dose is
the dose given.
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FCL2MxG={1±bcl3EXP[±PNA in days3Ln(2)/Tcl]}
FCLMxG={1±brf3EXP[±PNA in days3Ln(2)/Trf]}
FV={1±bvol3EXP[±PNA in days3Ln(2)/Tvol]}
where bcl, brf and bvol are parameters estimating the
fraction below `adult' values of parameters predicted at
birth; Tcl, Trf and Tvol describe the maturation half-lives of
the age-related changes in the parameters. FCL2MxG,
FCLMxG represent the formation and elimination clear-
ances of either M3G or M6G and FV morphine volume as a
fraction of standard 70 kg adult values, i.e. when AGE is
suf®ciently large that the exponential expression tends to
zero.
The effect of altered renal function on CLM3G and
CLM6G was modelled using an estimate of renal function in
children older than 1 week. Renal function was standardized
to a 40-yr-old adult male with a creatinine clearance of 6
litres h±1 and a serum creatinine of 85.947 mmol litre±1.24
This empirical model used age (PNA) as a covariate to
predict creatinine production rate with scaling constant
(Kage) for age:
FRF=85.947/creatinine3EXP(Kage3PNA/365±40).
Serum bilirubin (mmol litre±1) was used as a marker of
hepatic function and its effect on CL2M3G and CL2M6G
was modelled with an exponential function with a scaling
constant (Kbili):
FBILI=EXP(bilirubin3Kbili).
The clearance in a child with speci®c age, serum
creatinine and bilirubin was then predicted by multiplying
each of the covariate factors by the population parameter
value for a standard 70 kg adult.
CL2M3G=CL2M3Gstd3FCL2M3G3FBILI
CLM3G=CLM3Gstd3FCLM3G3FRF.
The quality of ®t of the pharmacokinetic model to the
data was assessed by visual examination of plots of
observed versus predicted concentrations. Models were
nested and an improvement in the objective function was
Table 1A Pharmacokinetic parameter estimates. These estimates are
standardized to a 70-kg person using an allometric size model. The
metabolite volumes of distribution (V3M, V6M) cannot be identi®ed with
the current study design and were ®xed at 23 and 30 litres per 70 kg, based
on studies by Penson and colleagues18 and Hanna and colleagues19 in adults.
CV=coef®cient of variation for the population parameter estimate;
SE=standard error of the estimate; CLT=population estimate for total
morphine CL (litres h±1 per 70 kg); V=volume of distribution for morphine
(litres per 70 kg); CL2M3G=formation clearance to M3G (litres h±1 per 70
kg); CL2M6G=formation clearance to M6G (litres h±1 per 70 kg);
CLM3G=clearance of M3G (litres h±1 per 70 kg); CLM6G=clearance of
M6G (litres h±1 per 70 kg); CLEX=unaccounted clearance; Err=residual error
Parameter Estimate CV (%) SE (%)
CLT 71.1 ±
C2LM3G 64.3 58.8 18.0
CL2M6G 3.63 82.2 14.0
CLM3G 17.4 43.0 16.0
CLM6G 5.8 73.8 20.2
CLEX 3.12 117.0 133.7
V 136 59.3 11.0
V3M 23 ®xed ± ±
V6M 30 ®xed ± ±
Err morphine (proportional) 0.36 11.6
Err M3G (additive) (ng ml±1) 7.09 36.2
Err M3G (proportional) 0.34 27.0
Err M6G (additive) (ng ml±1) 0.45 26.0
Err M6G (proportional) 0.30 16.9
Table 1B Covariate models and estimates for pooled population parameters.
Volume of distribution (litres):
V=[Vstd3(Wt/70)]3{1 + bvol3EXP[±PNA in days3Ln(2)/Tvol]}
bvol is a parameter estimating the fraction below V at birth; Tcl describes
the maturation half-life of the age-related change for V; PNA is postnatal age.
Formation clearance (litres h±1):
CL2M3G=[CL2M3Gstd3(Wt/70)
0.75]3{1±bcl3EXP[±PNA in days3Ln(2)/Tcl]}
CL2M6G=[CL2M6Gstd3(Wt/70)
0.75]3{1±bcl3EXP[±PNA in days3Ln(2)/Tcl]}
bcl is a parameter estimating the fraction below CL2M3G and CL2M6G at
birth; Tcl describes the maturation half-life of the age-related change for
CL2M3G and CL2M6G.
Metabolite clearance (litres h±1):
CLM3G=[CLM3Gstd3(Wt/70)
0.75]3{1±brf3EXP[±PNA in days3Ln(2)/Trf]}
CLM6G=[CLM6Gstd3(Wt/70)
0.75]3{1±brf3EXP[±PNA in days3Ln(2)/Trf]}
brf estimates the fraction below CLM3G and CLM6G and birth; Trf
describes the maturation half-life of the age-related change for CLM3G and
CLM6G.
Creatinine clearance44 in children older than 1 week: creatinine clearance
was standardized to a 40 year old person and centred about 85.947 mmol
litre±1. This empirical model used age (PNA) as a covariate to predict
creatinine production rate with scaling constant (Kage); e.g.
CLM3G=CLM3Gstd3(Wt/70)
0.75385.947/creatinine3EXP(Kage3PNA/365±
40)
Relationship of bilirubin to CLM3G and CLM6G:
CLM3G=CLM3Gstd3(Wt/70)
0.753EXP(bilirubin3Kbili)
Kbili is a scaling factor
Parameter Estimate SE (%)
bvol 0.391 28.4
Tvol (days) 26.3 72.2
bcl 0.834 6.4
Tcl (days) 88.3 37.4
brf 0.832 9.7
Trf (days) 129 49.8
Kage 0.0141 139.7
Kbili ±0.00203 33.2
Table 2 Covariance of pharmacokinetic parameters, expressed as the
correlation of population parameter variability
CL2M3G CL2M6G CLM3G CLM6G V
CL2M3G 1
CL2M6G 0.255 1
CLM3G 0.29 ±0.19 1
CLM6G ±0.17 0.76 0.066 1
V 0.557 ±0.02 0.342 ±0.227 1
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referred to the Chi-squared distribution to assess signi®-
cance; e.g. an objective function change (OBJ) of 3.84 is
signi®cant at a=0.05.
Results
The analysis used 1856 concentration observations from
184 subjects. The numbers of children given intermittent
bolus and those given morphine infusion were the same
(n=92). There were 106 boys and 78 girls. Mean (range) age
and weight of the patients were 195 (0±1070) days and 5.9
(1.9±16.8) kg. Parameter estimates, standardized to a 70-kg,
40-yr-old person, are shown in Table 1A. Covariate analysis
estimates are shown in Table 1B. The covariance of the
pharmacokinetic parameters, expressed as the correlation of
population parameter variability, was low (Table 2).
Table 3A shows metabolite formation and elimination
clearance estimate changes with age.
The volume of distribution of morphine increased
exponentially with a maturation half-life of 26.3 days
from 83 litres per 70 kg at birth to an adult value of 136 litres
per 70 kg (Fig. 2); formation clearance to M3G (Fig. 3A) and
M6G (Fig. 3B) increased with a maturation half-life of 88.3
days from 10.8 and 0.61 litres h±1 per 70 kg at birth to
predicted values of 64.3 and 3.63 litres h±1 per 70 kg in
adults respectively. At 6 months formation clearances were
80% of those predicted in adults. Formation maturation
rates for both metabolites were the same. The objective
function was not improved by using individual formation
maturation parameters for each metabolite. Metabolite
formation clearances decreased with increasing serum
bilirubin concentration (Fig. 4).
Metabolite elimination clearance of M3G and M6G
increased with a maturation half-life of 129 days from 3 and
0.98 litres h±1 per 70 kg at birth to predicted values of 17.3
and 5.8 litres h±1 per 70 kg in adults respectively (Fig. 5A
and B). This maturation curve is similar to that described for
the maturation of glomerular ®ltration rate in infants.25 The
effect of altered renal function (creatinine clearance) on
Table 3A Morphine and metabolite parameter estimate changes with age from the present study
Age V CL2M6G CL2M3G CLM3G CLM6G CLEX CLT base
(days) (litres per
70 kg
(litres h±1
per 70 kg)
(litres h±1
per 70 kg)
(litres h±1
per 70 kg)
(litres h±1
per 70 kg)
(litres h±1
per 70 kg)
(litres h±1
per 70 kg)
0 84 0.61 10.8 3.0 0.98 3.12 14.5
7 92 0.76 13.5 3.5 1.2 3.12 17.4
30 112 1.34 22.0 5.1 1.7 3.12 26.3
90 131 2.14 37.8 8.5 2.8 3.12 43.1
180 136 2.9 51.3 11.9 4.0 3.12 57.3
365 136 3.5 61.2 15.4 5.1 3.12 67.8
1000 136 3.63 64.3 17.3 5.8 3.12 71.1
Fig 2 Volume of distribution change with postnatal age. Individual
predicted volumes, standardized to a 70-kg person, from the NONMEM
post hoc step, are plotted against age. The solid line represents the non-
linear relation between volume of distribution and age.
Fig 3 (A) Individual predicted formation clearances to M3G, standardized
to a 70-kg person, from the NONMEM post hoc step, are plotted against
age. The solid line represents the non-linear relation between clearance
and age. (B) Individual predicted formation clearances to M6G,
standardized to a 70-kg person, from the NONMEM post hoc step, are
plotted against age.
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M3G elimination clearance unaccounted for by maturation
is shown in Figure 6. This effect appears minimal.
Figure 7A±C demonstrates the quality of ®t for pharma-
cokinetic data over the study time. The individual Bayesian
predictions for serum concentration of morphine, M3G and
M6G are compared with those observed. These predictions
are based on maximum a posteriori Bayesian estimates of
the parameters for each speci®c individual using their
observed data. The ®t is poorest for the prediction of serum
metabolite concentration after the initial loading dose of
morphine.
Total morphine clearance predictions (CLT) can be used
to calculate morphine hydrochloride infusion rates required
attaining steady-state serum concentration. Infusion rate is a
product of clearance and desired concentration. A mean
steady-state serum concentration of 10 ng ml±1 can be
achieved in children after non-cardiac surgery in an
intensive care unit with a morphine hydrochloride infusion
of 5 mg h±1 kg±1 at birth (term neonates, 3.3 kg), 8.5 mg h±1
kg±1 at 1 month (4 kg), 13.5 mg h±1 kg±1 at 3 months (6 kg),
18 mg h±1 kg±1 at 1 yr (10 kg) and 16 mg h±1 kg±1 for 1- to 3-
yr-old children (12±18 kg).
Discussion
Size has considerable impact on the estimation and inter-
pretation of pharmacokinetic parameters in children7 8 26
and has been unaccounted for in paediatric morphine
pharmacokinetic studies.5 27±32 The impact of size is
demonstrated in Table 3B and C, where reported clearance
estimates, standardized to a 70-kg person with an allometric
3
4
power model, show that clearance is similar to adults
within 6±12 months. Size was the primary covariate used in
our analysis of the effects of age and weight. This deliberate
choice was based on known biological principles. A great
many physiological, structural and time-related variables
scale predictably within and between species with weight
exponents of 0.75, 1 and 0.25 respectively.21 We used these
1
4
power models in this study rather than centred weight or
some other function of weight, because the 1
4
power models
have sound biological principles. West and colleagues22 23
have used fractal geometry to explain this phenomenon
mathematically. The 3
4
power law for metabolic rates was
Fig 4 Individual a posteriori Bayesian estimates for CL2M3G corrected
for size and age plotted against serum bilirubin. Formation clearance
decreases as serum bilirubin increases.
Fig 5 Individual a posteriori Bayesian estimates of CLM3G (A) are
plotted against postnatal age. The dashed line represents the maturation
of glomerular ®ltration rate (GFR; ml min±1 per 1.73 m2), scaled to
overlie CLM3G maturation (data from Bergstein).25 (B) Individual a
posteriori Bayesian estimates of CLM6G are plotted against postnatal
age.
Fig 6 The relationship of creatinine clearance to metabolite elimination
clearance of M3G, corrected for size and age. Changes in creatinine
clearance are accounted for by maturation of M3G clearance.
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derived from a general model that describes how essential
materials are transported through space-®lled fractal net-
works of branching tubes.22 23 These design principles are
independent of detailed dynamics and explicit models and
should apply to virtually all organisms. By choosing weight
as the primary covariate, the secondary effects of age could
be investigated. We had no prior biological model for the
effect of age on clearance or apparent volume, but assumed
®rst order processes, which are common in biology.
The total body clearance (CLT) was 80% of that of adults
by 6 months and 96% of that predicted in adults by 1 yr.
Morphine HCl CLT and its rate of maturation fall between
those described by McRorie and colleagues32 and those
described by others,30 33 when their estimates are standar-
dized to a 70-kg person with a 3
4
power model (Table 3C).
Our estimates are for the anhydrous morphine base rather
than sulphate or hydrochloride salts and were determined
using a population-based analysis. Differences may also be
related to the population studied and the nature of the illness
within that population.5 McRorie and colleagues32 and Lynn
and colleagues30 determined clearance by dividing infusion
rate by steady-state concentration. Patients who did not
achieve steady-state concentrations were excluded and it is
unclear from their papers if the morphine salt used in the
infusion and measured concentrations of morphine were
corrected for molecular weight. We predict that morphine
total clearance rises from 14.5 litres h±1 per 70 kg at birth to
71 litres h±1 per 70 kg in adults.
Based on the assumed values for metabolite volume of
distribution, the predominant morphine elimination path-
way is formation of M3G. Formation clearance to M3G and
M6G increased with maturation half-life of 88.3 days from
10.8 and 0.61 litres h±1 per 70 kg at birth to predicted values
of 64.3 and 3.63 litres h±1 per 70 kg at 3 yr respectively.
There are few data concerning morphine metabolite forma-
tion or elimination clearance in neonates and children.
Barrett and colleagues34 studied the pharmacokinetics of
morphine, M6G and M3G in 19 ventilated newborn infants
(24±41 weeks gestation) who were given diamorphine
infusions. The authors made the assumption that 55% of
administered morphine is converted to M3G and 10% to
M6G, based on adult literature.35 The CLT reported by
Barrett and colleagues 34 (4.6 ml min±1 kg±1, 7.2 litres h±1
per 70 kg) is similar to that observed in the study by Scott
and colleagues in premature neonates29 (Table 3B), but the
CL2M3G (2.5 ml min±1 kg±1, 4.0 litres h±1 per 70 kg) is half
of that in on our current study. We estimate the formation
clearance of M3G in 1-yr-old infants accounts for 86% of
morphine elimination. This has to be compared with a 55%
contribution proposed in adults.35 The CL2M6G (0.46
ml min±1 kg±1, 0.72 litres h±1 per 70 kg) is similar to our
estimate (0.61 litres h±1 per 70 kg). CLT observed in the
present study in term neonates is greater than that described
by others in premature neonates28 29 (4.6 ml min±1 kg±1, 7.2
litres h±1 per 70 kg), consistent with intrauterine develop-
ment of glucuronidation.1
The volume of distribution increased exponentially with a
maturation half-life of 26.3 days from 83 litres per 70 kg at
birth to 136 (CV 117%) l/70 kg at 6 months. A literature
review was unable to discern age related changes in volume
of distribution.4 However, the methods used in the literature
to determine volume of distribution vary greatly and it is
dif®cult to compare estimates. Individual studies, such as
that by Pokela and colleagues,36 report similar age-related
changes to ours. The volume of distribution increased from
91 (SD 28) litres per 70 kg in neonates 1±4 days old, 126 (SD
Fig 7 Quality of ®t for pharmacokinetic data over the study time period.
A line connects each subject's data. The individual a posteriori Bayesian
predictions for serum concentration of morphine (A), M3G (B) and M6G
(C) are compared with those observed. These predictions are based on
maximum a posteriori Bayesian estimates of the parameters for each
speci®c individual using their observed data.
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56) litres per 70 kg at 8±60 days and 168 (SD 105) litres per
70 kg at 61±180 days of age.
The metabolite volumes of distribution in neonates and
children are unknown. Penson and colleagues18 report a
volume of distribution for M3G (V3M) of 23.1 litres per 70
kg in adults. Adult estimates for the volume of distribution
for M6G (V6M) are from 8.4 to 30 litres per 70 kg.19 37±39
V6M is believed to be greater than V3M because of higher
lipophilicity at physiological pH;40 consequently a V6M of
30 litres per 70 kg was empirically chosen. The goodness of
®t was poorest for the prediction of serum metabolite
concentration after the initial loading dose of morphine
(Fig. 7) and may be attributable to ®xing VM at a set value
with no associated variability. The total elimination clear-
ance of M3G (CLM3G) of 17.4 (CV 43%) litres h±1 per 70
kg is greater than the renal M3G clearance described by
Penson and colleagues37 [10.1 (SD 2.9) litres h±1 70 kg] in
adults but total urinary morphine and metabolite recovery
was only 74.6% in that study. Penson and colleagues18 and
Lotsch and colleagues39 report a CLM6G of 9.4 (SD 2.8)
litres h±1 per 70 kg and 9.24 (SD 1.68) litres h±1 per 70 kg
respectively, greater than our estimate of 5.8 (CV 73.8%)
litres h±1 per 70 kg in young children.
The morphine metabolites M3G and M6G are water-
soluble compounds, enabling renal excretion. The time
course of metabolite elimination clearance is similar to that
of glomerular ®ltration rate (GFR), although clearance of
morphine glucuronide metabolites is greater (Fig. 5). This
may be attributable to renal tubular secretion35 41 42 and
non-renal elimination.35 43 Changes in GFR are usually
referenced to body surface area in children,25 a model that
approximates the 3
4
power model but uses 2/3 as the weight
exponent. Attempts to use the Cockcroft and Gault models44
to predict creatinine production rate failed. An empirical
formula based on age to predict creatinine production was
used. Creatinine production increased with age (Kage
0.0141) as opposed to adults, in whom production decreases
with age.44 The increase in children is assumed to be a
consequence of increasing muscle bulk with age as opposed
to the decrease in muscle bulk that occurs with age in adults.
The maturation of GFR is commonly estimated by
creatinine clearance. However, creatinine clearance (CrCl)
may result in overestimation as GFR declines because of
tubular secretion, changes in metabolic state altering
creatinine production, and measurement errors at low
concentrations signi®cantly altering CrCl estimation. We
demonstrated minimal effect attributable to altered renal
function (based on creatinine production) because matur-
ation of metabolite elimination clearance, which mirrored
GFR maturation, was already accounted for.
Serum bilirubin was used as a marker of hepatic function.
This is a very crude marker of hepatic function because
serum concentrations are dependent on both formation and
clearance of bilirubin. Bilirubin is metabolized in the liver
by another glucuronosyltransferase, UGT1A1, and does not
compete for the same metabolic pathway as morphine.1
Activity of this enzyme also increases immediately after
birth, reaching adult values at 3±6 months.45 It was possible
to relate bilirubin to metabolite formation. Formation
clearance to M3G in a 1-yr-old child, for example, is
reduced from 60 litres h±1 per 70 kg when serum bilirubin is
5 mmol litre±1 to 43 litres h±1 per 70 kg when bilirubin is 180
mmol litre±1.
Routes other than glucuronidation clear morphine in
humans. Renal clearance of unmetabolized morphine may
contribute up to 19% of CLT in infants younger than 3
months, 13% in older infants and 11% in adults.32 Sulphate
metabolism for morphine and paracetamol is active in
neonates and contributes approximately 6 litres h±1 per 70
kg for paracetamol clearance in 1-yr-old children and
adults.32 46 Faecal excretion and normorphine formation
contribute minimally. We were unable to quantify elimin-
ation speci®cally by these other routes. Unaccounted for
clearance of morphine contributed less than 5% in our
analysis.
Table 3B Morphine clearance changes with postconception age. Data taken
from Scott and colleagues29 (from van Lingen and colleagues47, with
permission)
PCA Weight Clearance CLTstd (CV%)
(weeks) (kg) (ml min±1 kg±1) (litres h±1 per 70 kg)
24±27 1.1 2.27 3.378 (47)
28±31 1.4 3.21 5.07 (49)
32±35 2.2 4.51 7.98 (44)
36±39 3.6 7.8 15.6 (32)
Table 3C Morphine sulphate clearance changes with postnatal age in term neonates. Data taken from Lynn and colleagues5 and McRorie and colleagues.32
*Weights are estimates only. Adult data from Kart et al.4
Age Weight* Clearance CLTstd Weight Clearance CLTstd
(days) (kg)
(Lynn et al.)
(ml min±1 kg±1) (litres h±1
per 70 kg)
(kg)
(McRorie
et al.)
(ml min±1 kg±1) (litres h±1
per 70 kg)
0±7 3 9.8 18.7 (12.0±30.6) 3.2 5.5 10.6 (6.2±16.3)
8±30 4 13.3 27.3 3.9 7.4 15.1 (6.9±38.4)
31±90 5.6 23.9 53.4 (37.3±74.4) 4.3 10.5 22.0 (20.5±42.0)
91±180 7.5 32.3 77.6 (44.5±125.2) 5.1 13.9 30.3 (18.2±52.6)
181±365 8.5 38.1 94.5 (44.6±172.1) 7.2 21.7 51.6 (13.7±68.0)
Adult 70 22 92.4 (CV% 38)
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